Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women

Archives of Internal Medicine

Volumn 164, Issue 10, 2004, Pages 1066-1076

  Hu, Gang ^a   Qiao, Qing ^a   Tuomilehto, Jaakko ^a   Balkau, Beverley ^a   Borch Johnsen, Knut ^a   Pyorala, Kalevi ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; EUROPE; FEMALE; GENDER; HUMAN; HYPERINSULINEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; METABOLIC DISORDER; MORTALITY; OBESITY; PREVALENCE; PRIORITY JOURNAL; SMOKING; WORLD HEALTH ORGANIZATION;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COHORT STUDIES; COMORBIDITY; EUROPE; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTICENTER STUDIES; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; SEX DISTRIBUTION; SURVIVAL ANALYSIS;

EID: 2442647863     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.164.10.1066     Document Type: Article

References (34)

1. Reaven GM. Banting Lecture 1988: role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
2. Liese AD, Mayer-Davis EJ, Haffner SM. Development of the multiple metabolic syndrome: an epidemiological perspective. Epidemiol Rev. 1998;20:157-172.
3. Laws A, Reaven GM. Insulin resistance and risk factors for coronary heart disease. Bailliers Clin Endocrinol Metab. 1993;7:1063-1078.
4. Alberti K, Zimmet P, for a WHO Consultation. Diagnosis and Classification of Diabetes Mellitus. Geneva, Swizerland: World Health Organization; 1999. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. Part 1.
5. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
6. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation: European Group for the Study of Insulin Resistance (EGIR). DiabetMed. 1999;16:442-443.
7. Wood DA, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention. Eur Heart J. 1998;19:1434-1503.
8. Pouliot M, Després JP, Melieux S, et al. Waist circumference and abdominal sagittal diameter: the best simple anthropometric measures of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol. 1994;73:460-468.
9. Bloomgarden ZT. American Association of Clinical Endocrinologists (AACE) Consensus Conference on the Insulin Resistance Syndrome: 25-26 August 2002, Washington, DC. Diabetes Care. 2003;26:933-939.
10. Trevisan M, Liu J, Bahsas FB, Menotti A. Syndrome X and mortality: a population-based study: Risk Factor and Life Expectancy Research Group. Am J Epidemiol. 1998;148:958-966.
11. Wilson PW, Kannel WB, Silbershatz H, D'Agostino RB. Clustering of metabolic factors and coronary heart disease. Arch Intern Med. 1999;159:1104-1109.
12. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-689.
13. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-2716.
14. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359.
15. McNeill AM, Girman CJ, Rosamond W, Ballantyne CM. A new definition of the metabolic syndrome predicts incident coronary heart disease and stroke. Presented at: 75th Scientific Session of the American Heart Association; November 17-20, 2002; Chicago, Ill. Abstract.
16. DECODE Study Group, Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetics? reanalysis of European epidemiological data. BMJ. 1998;317:371-375.
17. DECODE Study Group. Is fasting glucose sufficient to define diabetes? epidemiological data from 20 European studies. Diabetologia. 1999;42:647-654.
18. DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet. 1999;354:617-621.
19. DECODE Study Group. Glucose tolerance and cardiovascular mortality: comparison of the fasting and the 2-hour diagnostic criteria. Arch Intern Med. 2001;161:397-404.
20. Waterhouse J, Muir C, Correa P, Powell J, eds. Cancer Incidence in Five Continents. Vol 3. Lyon, France: IARC Scientific Publications; 1976:456.
21. Fleiss JH. The statistical basis of meta-analysis. Stat Methods Med Res. 1993;2:121-145.
22. Bonora E, Kiechl S, Willeit J, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes. 1998;47:1643-1649.
23. Rantala AO, Kauma H, Lilja M, Savolainen MJ, Reunanen A, Kesäniemi YA. Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects. J Intern Med. 1999;245:163-174.
24. Balkau B, Charles MA, Drivsholm T, et al. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab. 2002;28:364-376.
25. Park YW, Zhu S, Palaniappan L, Heshka S, Camethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2003;163:427-436.
26. Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care. 2003;26:575-581.
27. Resnick HE, Jones K, Ruotolo G, et al. Insulin resistance, the metabolic synr drome, and risk of incident cardiovascular disease in nondiabetic American Indians: the Strong Heart Study. Diabetes Care. 2003;26:861-867.
28. Mooy JM, Grootenhuis PA, de Vries H, et al. Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia. 1996;39:298-305.
29. Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol. 1993;137:959-965.
30. Yeni-Komshian H, Carantoni M, Abbasi F, Reaven GM. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care. 2000;23:171-175.
31. Després JP, Lamarche B, Mauriège P, Cantin B, Lupien PJ, Dagenais GR. Risk factors for ischaemic heart disease: is it time to measure insulin? Eur Heart J. 1996;17:1453-1454.
32. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537-544.
33. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.
34. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.